Latest News - AbbVie
Top Corporates Hub
AbbVie
Cramer’s ‘Absolute Favorite’ AbbVie Rises After Study Completions and Upgrade
08.10.2025 14:22
AbbVie Inc. (NYSE:ABBV) is one of Jim Cramer’s Recession-Proof Stock Picks. Cramer calls the stock his ‘absolute favorite,’ and it is followed by updates on the completion of two key studies. At the beginning of this month, AbbVie Inc. (NYSE:ABBV) announced the completion of a key study on ABBV-101’s food interaction and a Phase 2 […]
AbbVie Inc. (ABBV) Starts Building $70 Million Expansion of Its AbbVie Bioresearch Centre in Worcester, Massachusetts
08.10.2025 14:03
With significant hedge fund interest and trending on Reddit, AbbVie Inc. (NYSE:ABBV) secures a spot on our list of the 10 Best Non-Tech Stocks to Buy According to Reddit. As part of its $10 billion U.S. capital expenditure strategy to increase biologics manufacturing capacity, AbbVie Inc. (NYSE:ABBV) started building a $70 million expansion of its […]
Why AbbVie Stock Soared in September
08.10.2025 07:41
It was a month stuffed with several different kinds of wins for the pharmaceutical company.
AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor
06.10.2025 13:00
AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 2 ELATE trial evaluating the safety and efficacy of onabotulinumtoxinA (BOTOX®) compared to placebo for the treatment of upper limb essential tremor.
REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD
06.10.2025 11:05
REGENXBIO Inc. (Nasdaq: RGNX) today announced the completion of enrollment in the ATMOSPHERE® and ASCENT® pivotal studies evaluating surabgene lomparvovec (sura-vec, ABBV-RGX-314) in wet age-related macular degeneration (wet AMD) using subretinal delivery.
AbbVie to Host Third-Quarter 2025 Earnings Conference Call
02.10.2025 12:00
AbbVie (NYSE: ABBV) will announce its third-quarter 2025 financial results on Friday, October 31, 2025, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.
Defence Therapeutics Appoints Dr. Mark Lambermon as Head of Quality and Operations
02.10.2025 07:15
Montreal, Quebec--(Newsfile Corp. - October 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce the appointment of Mark Lambermon, PhD, as Head of Quality and Operations. Dr. Lambermon brings over 20 years of experience spanning pharmaceutical R&D, biotech innovation, and commercial manufacturing, with a proven track record in building and leading.
AbbVie (ABBV) Advances Parkinson’s Treatment With Tavapadon NDA
02.10.2025 06:55
AbbVie Inc. (NYSE:ABBV) ranks among the top picks for a retirement portfolio. The FDA received a New Drug Application from AbbVie Inc. (NYSE:ABBV) on September 26 for tavapadon, an experimental oral medication used once daily to treat Parkinson’s disease. The application is based on data from the Phase 3 TEMPO clinical trial, which assessed tavapadon […]
Leerink Raises AbbVie (ABBV) Price Target on Strong Business Performance
02.10.2025 06:08
AbbVie Inc. (NYSE:ABBV) ranks among the stocks with low beta that can beat market volatility. On September 24, Leerink Partners maintained its Outperform rating on AbbVie Inc. (NYSE:ABBV) and raised its price target on the company’s shares from $210 to $243. The increase comes after AbbVie Inc. (NYSE:ABBV) announced on September 11 that it had […]
Presbyopia Market Research Report 2025-2035 | FDA-Approved Eye Drops, Advanced IOLs and Personalized Medicine Drive Global Growth Amid Aging Population
01.10.2025 10:17
The global presbyopia market is rapidly expanding, driven by a growing aging population and advancements in diagnostic and treatment options. Presbyopia, an age-related vision condition affecting the eye's ability to focus on nearby objects, is typically diagnosed through comprehensive eye exams and advanced imaging techniques like OCT. The market is witnessing significant growth due to increased awareness, with innovations in non-invasive treatments such as FDA-approved eye drops and corrective
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
01.10.2025 09:25
If you are looking for dividend stocks that can provide a reliable, long-term income stream, consider buying AbbVie, Coca-Cola, and Chevron.
AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility
29.09.2025 16:00
AbbVie (NYSE: ABBV) today announced the start of construction of its new active pharmaceutical ingredient (API) manufacturing plant in North Chicago, Illinois. This is a significant milestone in AbbVie's ongoing efforts to expand its U.S. manufacturing network, capabilities and capacity.
AbbVie to launch ovarian cancer drug in UK at US price
29.09.2025 13:11
President Donald Trump has been demanding that drugmakers align domestic prices with the lowest levels paid by comparable high-income countries under the "most-favored-nation" policy. The U.S. pays nearly three times more for prescription drugs compared to other developed nations. Last week, Bristol Myers Squibb said it planned to launch schizophrenia drug Cobenfy in the UK next year at a price matching its U.S. list price.
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
29.09.2025 13:00
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
AbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-gynx)
29.09.2025 13:00
AbbVie (NYSE: ABBV) today announced plans to launch ELAHERE® (mirvetuximab soravtansine-gynx) in the U.K. at a list price equal to the U.S., reflecting the advanced innovation and value of the treatment for adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.1 ELAHERE is the first-and-only approved FRα-directed antibody drug
AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's Disease
26.09.2025 12:45
AbbVie (NYSE: ABBV) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tavapadon, a novel selective dopamine D1/D5 receptor partial agonist that was studied as a once daily oral treatment for Parkinson's disease.
H.C. Wainwright Affirms ‘Buy’ Rating on Atai Life Sciences N.V. (ATAI) on Psychedelic Prospects
20.09.2025 07:43
Atai Life Sciences N.V. (NASDAQ:ATAI) is one of the best healthcare penny stocks to buy now. On September 15, H.C. Wainwright reiterated a ‘Buy’ rating on the stock and a $15 price target. The positive stance follows a meeting between the research firm and the company’s CEO, Srinivas Rao, at the 27th Annual Global Investment […]
The Zacks Analyst Blog Highlights AbbVie, ServiceNow, Boeing, Tucows and and Ampco-Pittsburgh
19.09.2025 13:59
Zacks spotlights AbbVie, ServiceNow, Boeing, Tucows, and Ampco-Pittsburgh, detailing growth drivers, headwinds, and industry positioning.
3 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off
19.09.2025 09:44
Everything is going great for the stock market right now. But a plot twist could be on the way.